BLISS GVS PHARMA
|
|
BOM : 506197     NSE : BLISSGVS     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Upward Pledged Shares : None or < 25% |
Dec 13,2024 |
Price(EOD): ₹ 175.85
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 1,853.46 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
BLISS GVS PHARMA | 13.1% | 48.2% | 31.9% |
SUN PHARMACEUTICAL INDUSTRIES | 0.4% | 0.8% | 45.4% |
CIPLA | -1.5% | -5.1% | 20.3% |
DR REDDYS LABORATORIES | -0.7% | -1.3% | 13.8% |
ZYDUS LIFESCIENCES | -0.5% | 3% | 54.1% |
DIVIS LABORATORIES | -1.4% | 1.2% | 62% |
MANKIND PHARMA | 0% | 0.5% | 38.1% |
TORRENT PHARMACEUTICALS | 0.4% | 6.3% | 60.1% |
LUPIN | -1.5% | -0.6% | 72.3% |
FUNDAMENTAL ANALYSIS OF BLISS GVS PHARMA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF BLISS GVS PHARMA
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
25.75
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 71.96 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] 1.93
P/B Calculated based on Book Value of Rs 959.47 Cr
[Latest Year - Mar2024 - Consolidated Results ] 2.32
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 800.17 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
94% 35% 32% |
SHARE PRICE MOMENTUM OF BLISS GVS PHARMA
BLISS GVS PHARMA vs SENSEX
DEBT OF BLISS GVS PHARMA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.07 0.08 0.1 0.08 |
0.09 0.11 0.13 0.11 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF BLISS GVS PHARMA
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF BLISS GVS PHARMA
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
18.53% 20.82% 18.73% 16.23% |
2.74% -23.71% -39.61% -40.31% |
QtrlyTrend |
2 | |
Latest Qtr: Sep2024 | ||
Quarterly Result Analysis → |
BLISS GVS PHARMA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE MIDSMALLCAP | 0% | 4.7% | 37.1% |
S&P BSE SMALL CAP | -0.2% | 4.9% | 38.6% |
S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
S&P BSE HEALTHCARE | -1% | 1.4% | 45.2% |
You may also like the below Video Courses
FAQ about BLISS GVS PHARMA
Is BLISS GVS PHARMA good for long term investment?
As on Dec 13,2024, the Fundamentals of BLISS GVS PHARMA look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of BLISS GVS PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is BLISS GVS PHARMA UnderValued or OverValued?
As on Dec 13,2024, BLISS GVS PHARMA is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of BLISS GVS PHARMA ?
As on Dec 13,2024, the Intrinsic Value of BLISS GVS PHARMA is Rs. 130.21 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 90.74
Fair Value [Median EV / Sales Model] : Rs. 130.21
Fair Value [Median Price / Sales Model] : Rs. 132.74
Estimated Median Fair Value of BLISS GVS PHARMA : Rs. 130.21
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.